Dr. Stuart Elborn When it comes to formulating new and improved antibacterial treatments, scientists are in a race against the time it takes for today’s bacteria to mutate into more harmful, resistant strains. Even with today’s technology and advanced research practices, emerging pharmaceutical…

Young adults and children with cystic fibrosis in the United States have better lung function than those who live in the United Kingdom, despite the fact that both countries have well-developed healthcare systems. Differences in lung function may be a result of differences in healthcare structure, according to the…

Leerink Partners, a specialty investment bank in the field of healthcare, recently extended an invitation to Insmed Incorporated, the biopharmaceutical company behind a highly promising liposomal amikacin formulation to treat Pseudomonas aeruginosa infections in patients with cystic fibrosis (CF), to participate in a Rare Disease…

Any concern that may exist over cystic fibrosis patients receiving nasal live-attenuated influenza vaccine (LAIV) due to infection risk may be unfounded, according to a new study conducted by Constantina Boikos, MScPH, from McGill University in Montreal. Dr. Boikos and colleagues evaluated 168 cystic fibrosis patients, ages 2 to…

Josh Brown Tommy Bahama, an island lifestyle brand under Oxford Industries, Inc. that markets casual, sporting, and swimming apparel and footwear, has teamed up with Josh Brown of the New York Giants of the National Football League (NFL) for a cystic fibrosis (CF) fundraising campaign. The…

Drug development companies such as NovaBiotics that are devoted to designing and developing treatments for patients with difficult-to-treat, medically unmet diseases are often faced with the hurdle of recruiting enough patients to conduct the clinical trials necessary to approve new treatments. Recently, the hindrance has…

Development-stage drug development company, Parion Sciences, just announced a generous donation from the Cystic Fibrosis Foundation Therapeutics (CFFT) organization worth $3 million. This funding will be allotted to further research on the company’s latest experimental product for cystic fibrosis (CF) — a genetic…